$3.27 2.2%
CDXS Stock Price vs. AI Score (Last 150 days)
Data gathered: July 16

AI Score

Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Codexis

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics.

Price $3.27
Target Price Sign up
Volume 281,630
Market Cap $226M
Year Range $1.6 - $4.65
Dividend Yield 0%
Revenue per Employee $299,000
Industry Biotechnology

In the news

Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '2417M18M-720,000-12M-9.9M-0.160
Q4 '2327M13M14M-7.2M2.3M-0.100
Q3 '239.3M19M-9.9M-35M-5.8M-0.500
Q2 '2321M17M4.7M-12M-9.7M-0.170
Q1 '2313M20M-7M-23M-24M-0.340

Insider Transactions View All

Dorgan Byron L filed to sell 193,461 shares at $2.1.
November 17 '23
Norrett Kevin filed to buy 98,102 shares at $1.7.
September 12 '23
DILLY STEPHEN GEORGE filed to buy 438,878 shares at $1.7.
September 12 '23
Fitzgerald Margaret Nell filed to buy 81,420 shares at $1.7.
September 12 '23
Ryali Sriram filed to buy 123,441 shares at $1.7.
September 12 '23

What is the Market Cap of Codexis?

The Market Cap of Codexis is $226M.

How Many People Work at Codexis?

As of our latest update, Codexis employed approximately 248 people worldwide. However, it's important to note that Codexis' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Codexis' revenue per employee?

$299,000. To calculate Codexis' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Codexis?

Currently, the price of one share of Codexis stock is $3.27.

How can I analyze the CDXS stock price chart for investment decisions?

The CDXS stock price chart above provides a comprehensive visual representation of Codexis' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Codexis shares. Our platform offers an up-to-date CDXS stock price chart, along with technical data analysis and alternative data insights.

Does CDXS offer dividends to its shareholders?

As of our latest update, Codexis (CDXS) does not offer dividends to its shareholders. Investors interested in Codexis should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Codexis?

Some of the similar stocks of Codexis are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.